Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity.
暂无分享,去创建一个
Amir Lerman | Joerg Herrmann | Nicola Ferri | A. Lerman | J. Herrmann | A. Corsini | N. Ferri | Peter Siegl | P. Siegl | Alberto Corsini | Renee Benghozi | R. Benghozi
[1] P. Hoffmann,et al. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. , 2006, Journal of pharmacological and toxicological methods.
[2] B. Munos. Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.
[3] M. Kivimaki,et al. Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey. , 2011, European heart journal.
[4] A. Wu,et al. Biological variation and reference change value of high-sensitivity troponin T in healthy individuals during short and intermediate follow-up periods. , 2011, Clinical chemistry.
[5] J. Cummings,et al. Quinidine Syncope: Paroxysmal Ventricular Fibrillation Occurring during Treatment of Chronic Atrial Arrhythmias , 1964, Circulation.
[6] M. Kivimäki,et al. Antidepressant Medication Use, Weight Gain, and Risk of Type 2 Diabetes , 2010, Diabetes Care.
[7] D. Goff,et al. Adverse Cardiac Effects Associated With Clozapine , 2005, Journal of clinical psychopharmacology.
[8] Liudmila Polonchuk,et al. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. , 2008, Journal of pharmacological and toxicological methods.
[9] P. Soulié,et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C Michael Stein,et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. , 2009, The New England journal of medicine.
[11] N. Petrelli,et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] F. Zitman,et al. Depression Is Associated With Decreased Blood Pressure, but Antidepressant Use Increases the Risk for Hypertension , 2009, Hypertension.
[13] T. Nolin,et al. Antimicrobial-associated QT interval prolongation: pointes of interest. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] S. Lippman,et al. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] C. Hudis,et al. Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer. , 2009 .
[16] J. Ehrhart,et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone , 2008, British journal of pharmacology.
[17] R. Owens. QT Prolongation with Antimicrobial Agents , 2012, Drugs.
[18] J. Francis,et al. Psychotropic medication use and risk of adverse cardiovascular events in women with suspected coronary artery disease: outcomes from the Women’s Ischemia Syndrome Evaluation (WISE) study , 2009, Heart.
[19] R. Ohno,et al. Prolongation of the QT Interval and Ventricular Tachycardia in Patients Treated with Arsenic Trioxide for Acute Promyelocytic Leukemia , 2000, Annals of Internal Medicine.
[20] G. Martinelli,et al. Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy , 2004, Circulation.
[21] V. Heinemann,et al. Anticancer therapy induced cardiotoxicity: review of the literature , 2010, Anti-cancer drugs.
[22] P. O'Brien. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. , 2008, Toxicology.
[23] Matthew M. Burg,et al. Effects of Antidepressant Medication on Morbidity and Mortality in Depressed Patients After Myocardial Infarction , 2005 .
[24] E. Perez,et al. Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104) , 2008 .
[25] V. Zagonel,et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. , 2000, Journal of the American College of Cardiology.
[27] R. Paoletti,et al. Biomarkers for atherosclerosis: pathophysiological role and pharmacological modulation , 2006, Current opinion in lipidology.
[28] E. Perez,et al. A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .
[29] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[30] S. Willich,et al. [Is the determination of biomarkers worth its price? Review of the literature taking brain natriuretic peptides (BNP) as an example]. , 2010, Herz.
[31] G. Minotti,et al. In vitro modeling of the structure–activity determinants of anthracycline cardiotoxicity , 2006, Cell Biology and Toxicology.
[32] J. Lieberman,et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. , 2003, The American journal of psychiatry.
[33] Jean-Pierre Valentin,et al. Reducing QT liability and proarrhythmic risk in drug discovery and development , 2010, British journal of pharmacology.
[34] Q. Bashir,et al. Cardiotoxicity of cancer therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Perry D Moerland,et al. MiR423-5p As a Circulating Biomarker for Heart Failure , 2010, Circulation research.
[36] J. Vázquez-Barquero,et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. , 2007, The Journal of clinical psychiatry.
[37] L. Aronne,et al. Weight gain in the treatment of mood disorders. , 2003, The Journal of clinical psychiatry.
[38] S. Meikle,et al. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. , 2011, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.
[39] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[40] P. N. Anderson,et al. High dose cyclophosphamide therapy in solid tumors: Therapeutic, toxic, and immunosuppressive effects , 1975 .
[41] H L Greene,et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.
[42] C. Zielinski,et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Michael J Ackerman,et al. Blockade of HERG channels by HIV protease inhibitors , 2005, The Lancet.
[44] B. Guth. Preclinical cardiovascular risk assessment in modern drug development. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.
[45] S. Connolly,et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. , 2009, The New England journal of medicine.
[46] R. Donehower,et al. Taxol: twenty years later, the story unfolds. , 1991, Journal of the National Cancer Institute.
[47] S. Wolfe,et al. Timing of new black box warnings and withdrawals for prescription medications. , 2002, JAMA.
[48] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[49] D. Faxon,et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echoca , 2003, Journal of the American College of Cardiology.
[50] D. Karnofsky,et al. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia , 1967, Cancer.
[51] M Markert,et al. Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies. , 2009, Journal of pharmacological and toxicological methods.
[52] E. Van Cutsem,et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[53] D. V. Von Hoff,et al. Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.
[54] Marc Buyse,et al. Adjuvant trastuzumab in HER2-positive breast cancer. , 2011, The New England journal of medicine.
[55] J. Lewin,et al. Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin , 2007, Clinical Cancer Research.
[56] A. Jaffe,et al. Troponin: the biomarker of choice for the detection of cardiac injury , 2005, Canadian Medical Association Journal.
[57] A. Janin,et al. Adverse events in phase-I studies: a report in 1015 healthy volunteers , 1998, European Journal of Clinical Pharmacology.
[58] D. Celermajer,et al. Myocarditis and cardiomyopathy associated with clozapine , 1999, The Lancet.
[59] Hugo M Vargas,et al. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals , 2013, Expert opinion on drug safety.
[60] J. McMurray,et al. Increased mortality after dronedarone therapy for severe heart failure. , 2008, The New England journal of medicine.
[61] L. Køber,et al. Prognosis in Heart Failure and the Value of &bgr;-Blockers Are Altered by the Use of Antidepressants and Depend on the Type of Antidepressants Used , 2009, Circulation. Heart failure.
[62] M. Milella,et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials , 2008, Breast Cancer Research and Treatment.
[63] A. Nakamura,et al. Neuregulin Receptor ErbB2 Localization at T-tubule in Cardiac and Skeletal Muscle , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[64] M. Lindquist,et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study , 2001, BMJ : British Medical Journal.
[65] R. Testa,et al. Aged-related increase of high sensitive Troponin T and its implication in acute myocardial infarction diagnosis of elderly patients , 2012, Mechanisms of Ageing and Development.
[66] Greg Yothers,et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] Tatsuya Morita,et al. Torsades de pointes caused by a small dose of risperidone in a terminally ill cancer patient. , 2004, Psychosomatics.
[68] C. Cipolla,et al. The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. , 2010, Progress in cardiovascular diseases.
[69] Mario Plebani,et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. , 2010, European heart journal.
[70] F. Ognibene,et al. High-Dose Ifosfamide Is Associated with Severe, Reversible Cardiac Dysfunction , 1993, Annals of Internal Medicine.
[71] D J Gallacher,et al. Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: current recommendations from the Safety Pharmacology Society. , 2012, Journal of pharmacological and toxicological methods.
[72] Randolph P. Martin,et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. , 2011, The American journal of cardiology.
[73] James L Stevens,et al. The future of drug safety testing: expanding the view and narrowing the focus. , 2009, Drug discovery today.
[74] W. V. R. Vieweg,et al. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low‐dose quetiapine , 2005, Acta psychiatrica Scandinavica.
[75] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[76] M. Pfreundschuh,et al. NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity , 2005, Circulation.
[77] J. Ferrières,et al. Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.
[78] B. Pollock,et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. , 1998, JAMA.
[79] G. Hortobagyi,et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma , 1989, Cancer.
[80] G. Martinelli,et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[81] S. Soignet,et al. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] A. Burnett,et al. Chemotherapy‐induced cardiotoxicity: current practice and prospects of prophylaxis , 2002, European journal of heart failure.
[83] G. Bonadonna,et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] Apurva A Desai,et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[85] D. Slamon,et al. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. , 2009, Journal of the National Cancer Institute.
[86] A. Caraceni,et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[88] H. Nasrallah,et al. Medical Illness and Schizophrenia , 2003 .
[89] S. Shaw,et al. Effect of Antipsychotic Medications on Glucose and Lipid Levels , 2011, Journal of clinical pharmacology.
[90] F. Veglia,et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] C Michael Stein,et al. Azithromycin and the risk of cardiovascular death. , 2012, The New England journal of medicine.
[92] J. Hartikainen,et al. QT dispersion and late potentials during doxorubicin therapy for non‐Hodgkin’s lymphoma , 1999, Journal of internal medicine.
[93] K. Zareba. Dronedarone: a new antiarrhythmic agent. , 2006, Drugs of today.
[94] Richard P. Lewis,et al. ACC/AHA guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Clinical Application of Echocard , 1990, Circulation.
[95] Charles R Partridge,et al. In vitro models to evaluate acute and chronic injury to the heart and vascular systems. , 2005, Toxicology in vitro : an international journal published in association with BIBRA.
[96] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[97] S. Pettit,et al. Cardiovascular Function in Nonclinical Drug Safety Assessment , 2011, International journal of toxicology.
[98] J. Sørensen,et al. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine , 2006, Cancer Chemotherapy and Pharmacology.
[99] R. Shah,et al. Can pharmacogenetics help rescue drugs withdrawn from the market? , 2006, Pharmacogenomics.
[100] D. Johns,et al. Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction , 2012, Clinical pharmacology and therapeutics.
[101] A. Camm,et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.
[102] D. Green,et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] R. Califf,et al. Antidepressant use, depression, and survival in patients with heart failure. , 2008, Archives of internal medicine.
[104] S. Verma,et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer , 2008, Cancer.
[105] G. Pagès,et al. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[106] L. Burke,et al. Symptomatic Cardiotoxicity Associated with 5‐Fluorouracil , 1997, Pharmacotherapy.
[107] K. Felmingham,et al. Impact of Depression and Antidepressant Treatment on Heart Rate Variability: A Review and Meta-Analysis , 2010, Biological Psychiatry.
[108] C. Michael Stein,et al. Oral erythromycin and the risk of sudden death from cardiac causes , 2004 .
[109] Rob Wallis,et al. A framework to assess the translation of safety pharmacology data to humans. , 2009, Journal of pharmacological and toxicological methods.
[110] J. Potter,et al. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. , 2004, The Australian and New Zealand journal of psychiatry.
[111] J. Valentin,et al. An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing risk , 2010, British journal of pharmacology.
[112] C. Cipolla,et al. Troponin I and cardiovascular risk stratification in patients with testicular cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] S. Srinivas,et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[114] Richard P. Lewis,et al. ACC/AHA Guidelines for the Clinical Application of Echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardio , 1997, Circulation.
[115] P. Sanders,et al. Cardiovascular Adverse Effects of Antipsychotic Drugs , 2000, Drug safety.
[116] M. Caulfield,et al. Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.
[117] J. McNeil,et al. Clozapine-Associated Myocarditis , 2007, Drug safety.
[118] J. Karlowsky,et al. Review of Macrolides and Ketolides , 2012, Drugs.
[119] D. Roden. Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.
[120] H. Duff,et al. Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial. , 1995, American heart journal.
[121] M. Eller,et al. Azithromycin and terfenadine: Lack of drug interaction , 1995, Clinical pharmacology and therapeutics.
[122] F. T. ten Cate,et al. Factors affecting sensitivity and specificity of diagnostic testing: dobutamine stress echocardiography. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[123] R. Wallis,et al. Integrated risk assessment and predictive value to humans of non‐clinical repolarization assays , 2010, British journal of pharmacology.
[124] M. Goldberg,et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. , 1986, Blood.
[125] M. Somerfield,et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[126] S. Lipshultz,et al. Anthracycline-induced cardiotoxicity in children and young adults. , 1998, Critical reviews in oncology/hematology.
[127] W Suter,et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? , 2011, British journal of pharmacology.
[128] R. Rubinshtein,et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. , 2010, European heart journal.
[129] S. Wallace,et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.
[130] H. Dickinson,et al. Cardioprotective interventions for cancer patients receiving anthracyclines. , 2011, The Cochrane database of systematic reviews.
[131] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[132] J. Syrios,et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study , 2007, Journal of Cancer Research and Clinical Oncology.
[133] R. Hobbs. Using BNP to diagnose, manage, and treat heart failure. , 2003, Cleveland Clinic journal of medicine.
[134] S. Willich,et al. Sind Biomarker ihr Geld wert? , 2010, Herz.
[135] Marek Pawlicki,et al. Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.
[136] R. Berg,et al. Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. , 1992, Journal of the American College of Cardiology.
[137] Alan S. Pearlman,et al. ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echoca , 2003, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[138] Salim Yusuf,et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[139] E. Perez,et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. , 2008, Mayo Clinic proceedings.
[140] O. Spigset,et al. Myocarditis Related to Clozapine Treatment , 2001, Journal of clinical psychopharmacology.
[141] T. Heinrich,et al. Torsades de pointes associated with ziprasidone. , 2006, Psychosomatics.
[142] F. Ponti,et al. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology , 2012, Internal and Emergency Medicine.
[143] M. Hayden,et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[144] J P Kennedy,et al. Preliminary assessment of an image analysis method for the evaluation of pharmaceutical coatings. , 1997, Pharmaceutical development and technology.
[145] Mansour Razminia,et al. Clozapine induced myopericarditis: early recognition improves clinical outcome. , 2006, American journal of therapeutics.
[146] W. Schmiegel,et al. 5-Fluorouracil induces arterial vasocontractions. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.